Claims for Patent: 9,931,414

Summary for Patent: 9,931,414

Title:	Pyrrolobenzodiazepine-antibody conjugates
Abstract:	Conjugates of an antibody that binds to CD19 with PBD dimers.
Inventor(s):	Van Berkel; Patricius Hendrikus Cornelis (Lausanne, CH), Howard; Philip Wilson (London, GB)
Assignee:	MEDIMMUNE LIMITED (Cambridge, GB) ADC THERAPEUTICS S.A. (Epalinges, CH)
Application Number:	14/434,816
Patent Claims:	1. A conjugate of formula ##STR00135## ##STR00136## where Ab is an antibody which is an antibody that binds to CD19, the antibody comprising a VH domain having the sequence of SEQ ID NO. 2, optionally further comprising a VL domain having the sequence of SEQ ID NO. 8; and wherein the drug loading is from 1 to 8. 2. The conjugate according to claim 1 wherein the antibody comprises a VH domain paired with a VL domain, the VH and VL domains having sequences of: SEQ ID NO. 2 paired with SEQ ID NO. 8. 3. The conjugate according to claim 1 wherein the antibody is an intact antibody. 4. The conjugate according to claim 1 wherein the antibody is humanised, deimmunised or resurfaced. 5. The conjugate according to claim 1, wherein the drug loading is 1, 2, 3, or 4. 6. A mixture of the conjugates according to claim 1, wherein the average value of the drug loading is about 2 to about 5. 7. The conjugate according to claim 1, wherein said conjugate comprises one of more conjugates selected from the group consisting of ConjA, ConjD and ConjE for use in treating a CD19 overexpressing cancer. 8. The conjugate according to claim 7, wherein the conjugate is ConjE. 9. A pharmaceutical composition comprising the conjugate of claim 1 and a pharmaceutically acceptable diluent, carrier or excipient. 10. The pharmaceutical composition of claim 9 further comprising a therapeutically effective amount of a chemotherapeutic agent. 11. A method of treating a CD19 overexpressing cancer comprising administering to a patient the pharmaceutical composition of claim 9 wherein said conjugate comprises one of more conjugates selected from the group consisting of ConjA, ConjD and ConjE. 12. The method of claim 11 wherein the patient is administered a chemotherapeutic agent, in combination with the conjugate. 13. A method of claim 11 wherein said conjugate is ConjE. 14. The method according to claim 12, wherein the chemotherapeutic agent is rituximab. 15. The method according to claim 13, wherein the chemotherapeutic agent is rituximab. 16. The conjugate according to claim 2, wherein the conjugate is formula ConjE.

Details for Patent 9,931,414

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2039-02-26
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2039-02-26